Saturday, September 23, 2023
Saturday, September 23, 2023

Levee Medical Secures $4.3M Strategic Investment to Accelerate Clinical Development of the Voro Urologic Scaffold, Designed to Improve Robotic Prostatectomy Outcomes

Levee Medical, a clinical-stage medical device company designing solutions to improve surgical outcomes following prostate cancer, announced today it has raised a total of $4.3 million in oversubscribed funds. Additionally, Levee Medical successfully treated the first study participants in its first-in-human (FIH) study, demonstrating initial safety data for the Voro™ Urologic Scaffold.  The trial will evaluate the safety and performance of the Voro Urologic Scaffold as a prophylactic treatment for post-prostatectomy stress urinary incontinence.

“Today we celebrate two incredible accomplishments for Levee Medical and the Voro Urologic Scaffold,” says Bruce Choi, Founder and CTO of Levee Medical. “This latest funding will serve as a powerful catalyst, propelling our clinical and regulatory efforts forward, expediting the path to commercialization, and facilitating the development and execution of a robust clinical strategy for our groundbreaking technology. With the support of our valued investors and dedicated team, we are poised to make a profound impact on patients undergoing surgical treatment for prostate cancer.”

The Voro Urologic Scaffold is the first and only bioresorbable device designed to be placed during the robotic prostatectomy procedure for the treatment of urinary incontinence. It is designed to reduce the stress on the urinary sphincter by managing the geometry of the bladder neck and maintaining urethral length, which is the best predictor of post-op incontinence.

“I am thrilled to say the first implant of the Voro Urologic Scaffold in the ARID study was a success,” states Michael Ferrandino, M.D., urologist at Colorado Urology in Westminster, CO. “The resorbable scaffold integrated into the robotic procedure and we were able to increase the urethral length. I firmly believe this approach can provide patients with the invaluable benefit of early continence after undergoing a robotic prostatectomy. The Voro Urologic Scaffold has the potential to significantly expedite the recovery process and enhance outcomes.”

In addition to these significant milestones, Levee Medical has also expanded its leadership team with the recent hire of Tessa Yamut, as Executive Vice President of Clinical and Regulatory Affairs. Tessa is a seasoned veteran in the medical device industry, with a remarkable track record spanning nearly 30 years, including 24 years in senior management roles. Her expertise shines through in her ability to navigate the complex landscape of regulatory, clinical, and reimbursement challenges for emerging companies. Her innovative and creative approach, combined with her unique skills, has proven instrumental in successfully de-risking, and expediting the approval process for Class I, II, and III medical devices both domestically and internationally.

Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Lipogems® Announces 140 Independent Peer Reviewed Publications with 5 Years of Follow up in Orthopaedics

Giorgio Ninzoli, President of Lipogems International. "The gold standard for evidence is 1 year follow up and we are excited to report 5 years follow up with positive results after a single injection of MicroFat."

Study Outcomes Could Provide Insights Into New Targeted Treatments to Manage this Challenging Disease

The study aims to determine if immediate biological preservation of patient-derived chordoma tumor tissue, collected intraoperatively and implanted for serial sampling in translational research, will provide new insights into the biological weakness of the disease and contribute to developing improved treatment therapies reports NICO.

Study Validates Lunit AI as a Game-Changer, Poised to Replace One Human Reader in Breast Cancer Screening

Utilizing Lunit INSIGHT MMG, an FDA-cleared and CE-marked AI solution for mammography analysis, this research backs AI's potential to replace one human reader under Europe's double reading guideline and underscores its capacity to alleviate the strain on radiologists.

MedAlliance Announces Enrollment of over 1,660 Patients in Landmark SELUTION DeNovo Study

SELUTION DeNovo Study is the largest DEB study ever initiated, involving up to 70 participating sites across 15 countries. Patients are randomized before any vessel preparation to reflect current medical practice and to reduce bias.  The objectives of the study are to demonstrate non-inferiority at both one and five years, and superiority for target vessel failure (TVF) at five years.

Vitestro Starts Largest-scale Clinical Trial Globally for its Autonomous Blood Drawing Device, with Enrolment of First Patients in A.D.O.P.T.

Vitestro expects to obtain CE marking by the end of 2024. The first 350 patients have currently been enrolled the A.D.O.P.T. (Autonomous Optimization and Performance Tests for Blood Testing) Trial at study site Result Laboratorium in the Albert Schweitzer Hospital. Investigational partners, in addition to Result Laboratorium - Albert Schweitzer Hospital, are St. Antonius, OLVG Lab and Amsterdam UMC.

By using this website you agree to accept Medical Device News Magazine Privacy Policy